iohexol has been researched along with 2019 Novel Coronavirus Disease in 7 studies
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression." | 5.41 | ( Bonno, M; Bridges, C; Chertow, GM; Correa-Rotter, R; Enoksen, IT; Eriksen, BO; Fuskevåg, OM; Georgiou, A; Greene, T; Gupta, S; Heerspink, HJL; Hirayama, M; Irwin, JM; Jenssen, TG; Johnson, JL; Jongs, N; Karaca-Mandic, P; Kashihara, N; Langkilde, AM; Mathisen, UD; McMurray, JJV; Melsom, T; Norvik, JV; Ogawa, M; Rossing, P; Rudisill, ME; Sen, S; Shiono, A; Simon, K; Sjöström, CD; Solbu, MD; Stefánsson, BV; Stefansson, V; Tanaka, S; Toto, RD; Toyoda, H; Wadsworth, DD; Wheeler, DC, 2021) |
| " However, little information was available about whether ICM-derived DBPs are toxic to aquatic organisms." | 1.91 | Disinfection byproducts of iopamidol, iohexol, diatrizoate and their distinct acute toxicity on Scenedesmus sp., Daphnia magna and Danio rerio. ( Liu, H; Watson, P; Yang, F; Yang, X; Zhou, N, 2023) |
| "A recent coronavirus disease 2019-related shutdown of the main production facility of iohexol in China has led to massive shortages of iodinated contrast material across the globe." | 1.72 | Navigating Supply Chain Disruptions of Iodinated Contrast Agent for Neuroimaging and How Business Intelligence Can Help the Decision Process. ( Amukotuwa, SA; Bammer, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grist, TM | 1 |
| Canon, CL | 1 |
| Fishman, EK | 1 |
| Kohi, MP | 1 |
| Mossa-Basha, M | 1 |
| Bammer, R | 1 |
| Amukotuwa, SA | 1 |
| Gupta, S | 1 |
| Georgiou, A | 1 |
| Sen, S | 1 |
| Simon, K | 1 |
| Karaca-Mandic, P | 1 |
| Shiono, A | 1 |
| Bonno, M | 1 |
| Toyoda, H | 1 |
| Ogawa, M | 1 |
| Tanaka, S | 1 |
| Hirayama, M | 1 |
| Johnson, JL | 1 |
| Wadsworth, DD | 1 |
| Rudisill, ME | 1 |
| Irwin, JM | 1 |
| Bridges, C | 1 |
| Melsom, T | 1 |
| Norvik, JV | 1 |
| Enoksen, IT | 1 |
| Stefansson, V | 1 |
| Mathisen, UD | 1 |
| Fuskevåg, OM | 1 |
| Jenssen, TG | 1 |
| Solbu, MD | 1 |
| Eriksen, BO | 1 |
| Jongs, N | 1 |
| Chertow, GM | 1 |
| Greene, T | 1 |
| McMurray, JJV | 1 |
| Langkilde, AM | 1 |
| Correa-Rotter, R | 1 |
| Kashihara, N | 1 |
| Rossing, P | 1 |
| Sjöström, CD | 1 |
| Stefánsson, BV | 1 |
| Toto, RD | 1 |
| Wheeler, DC | 1 |
| Heerspink, HJL | 1 |
| Lardieri, G | 1 |
| Kennady, EH | 1 |
| Yeaman, C | 1 |
| Schenkman, N | 1 |
| Zhou, N | 1 |
| Liu, H | 1 |
| Yang, X | 1 |
| Watson, P | 1 |
| Yang, F | 1 |
| Purtill, C | 1 |
| Dhesi, M | 1 |
| Haber, D | 1 |
| D Antonio, N | 1 |
| Hickok, NJ | 1 |
| Simon, JI | 1 |
| Viguier, A | 1 |
| Delamarre, L | 1 |
| Duplantier, J | 1 |
| Olivot, JM | 1 |
| Bonneville, F | 1 |
1 review available for iohexol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
International Iohexol Shortage: Alternative Contrast Agents and Imaging Procedures for the Urologist.
Topics: Contrast Media; COVID-19; Diatrizoate; Humans; Iohexol; Urologists | 2023 |
1 trial available for iohexol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; COVID-19; Cross-Sectional Studies; Diabetes Mellitus | 2021 |
5 other studies available for iohexol and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Short-, Mid-, and Long-term Strategies to Manage the Shortage of Iohexol.
Topics: Contrast Media; COVID-19; Humans; Iohexol; Pandemics | 2022 |
Navigating Supply Chain Disruptions of Iodinated Contrast Agent for Neuroimaging and How Business Intelligence Can Help the Decision Process.
Topics: Contrast Media; COVID-19; Humans; Intelligence; Iohexol; Neuroimaging | 2022 |
Disinfection byproducts of iopamidol, iohexol, diatrizoate and their distinct acute toxicity on Scenedesmus sp., Daphnia magna and Danio rerio.
Topics: Animals; Contrast Media; COVID-19; Daphnia; Diatrizoate; Disinfection; Halogenation; Humans; Iodine | 2023 |
Multiple Sterile Withdrawals from Iohexol Bottles Does Not Increase Contamination Risk.
Topics: Communicable Disease Control; Contrast Media; COVID-19; Humans; Iohexol | 2023 |
Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection.
Topics: Aged; Anticoagulants; Betacoronavirus; Biomarkers; Brain Ischemia; Carotid Artery Thrombosis; Comput | 2020 |